胸腺五肽联合干扰素治疗慢性湿疹的疗效观察

目的：探讨胸腺五肽联合干扰素治疗慢性湿疹的临床效果及安全性。方法：随机将2009-2012年我科收治的60例慢性湿疹患者分为两组，治疗组30例在给予相应的抗组胺药、非特异性抗过敏治疗的基础上加用胸腺五肽针10mg与干扰素α-2b200万u交替肌注，对照组30例只给予抗组胺药、非特异性抗过敏治疗，两组均在3周后观察其治疗效果及不良反应的发生情况。结果：治疗三周后，治疗组总有效率为70％，对照组总有效率为33．33％，两组总有效率比较差异有统计学意义（P〈0．05）。两组不良反应的发生率比较并无统计学差异（P〉0．05）。结论：胸腺五肽联合干扰素治疗慢性湿疹的临床疗效显著，副作用较小，安全性较高，值得临床推广应用。

Clinical Observation on the Efficacy of Thymopoietin-5 and Interferon in the Treatment of Chronic Eczema

Objective： To explore the clinical efficacy and safety of thymopoietin-5 combined with interferon in the treatment of chronic eczema. Methods： 60 cases with chronic eczema hospitalized in our department from 2009 to 2012 were randomly divided into two groups, 30 cases in the treatment group were treated with antihistamines, non-specific anti-allergic therapy as well as alternating injection of thymopoietin-5 10rag/day and interferon α-2b 2x 106 U/day. 30 cases in the control group were only given antihistamines, non-specific anti-allergic therapy. The clinical efficacy and adverse effects were observed after three weeks. Results： Three weeks after treatment, the total effective rate of treatment group was 70%, which was significantly higher than that in the control group （33.33%, P〈 0.05）. No significant difference of incidence of adverse reactions was observed between the two groups （P〉0.05）. Conclusion： Thymopoietin-5 plus interferon was effective and safe in the treatment of chronic eczema, it was showed good efficacy with little adverse effect and worth being further widely popularized in clinic.